+ Watch THLD
on My Watchlist
A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer.
Threshold has been gleefully destroying shareholder value for as long as I've been following biotech. The tried and true formula: Initiate trial. Dilute. Trial fails. Dilute. Reverse split. Initiate trial. Rinse, lather, repeat. Four years ago Threshold was impoverishing their investors with a drug called glufosfamide. Now they're doing the same thing with TH-302. Similar price, similar market cap, just another hundred million or so of investor's money blown.'
Might want to close this out zz.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions